Clinical trial NCT00389285: Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma
Official title: A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety and Pharmacokinetics of Recombinant Interleukin 21 (rIL-21) Administered Concomitantly With Sorafenib (Nexavar) in Subjects With Metastatic Renal Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Carcinoma, Renal Cell
Keywords: Carcinoma, renal cell
interleukin-21
sorafenib
Immunotherapy
Lead sponsor: ZymoGenetics
Sponsor class: INDUSTRY
First posted: 2006-10-18
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate whether recombinant IL-21 used in combination with sorafenib is safe for patients with metastatic renal cell carcinoma (RCC).

Detailed description: This is a Phase 1/2 open-label dose-escalation study of rIL-21 given in combination with sorafenib to patients with metastatic RCC. The Phase 1 part of this study will estimate the maximum tolerated dose of rIL-21 given for 1 treatment course (consisting of two 5-day cycles of rIL-21) in combination with a standard dose of sorafenib administered during a 6-week treatment course. Increasing doses of rIL-21 will be studied sequentially in different groups of patients. The Phase 2 part of the study will further evaluate the safety and preliminary antitumor activity of rIL-21 at the dose recommended from Phase 1 in combination with sorafenib. Patients will be evaluated for safety over the course of the study. Disease evaluation (tumor restaging) will be performed during the last week of each 6-week treatment course. Patients with stable disease or better at this evaluation may go on to receive additional treatment courses. Patients may be in the study for 2 to 7 months.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of RCC of predominantly clear cell histology
* Either no prior treatment or a maximum of 2 prior treatment regimens for metastatic RCC that included no more than 1 treatment regimen targeting the vascular endothelial growth factor (VEGF) pathway (Phase 1 only)
* At least 1 but no more than 2 prior systemic therapies for metastatic RCC that included no more than 1 therapy targeting the VEGF pathway (Phase 2 only)
* Disease measurable per the Response Evaluation Criteria in Solid Tumors (RECIST) (Phase 2 only)

Exclusion Criteria:

* Presence of acute infection or other significant systemic illness
* Central nervous system involvement by malignancy
* History of other cancer within 5 years
* Previously received rIL-21 or sorafenib

Primary outcomes:
measure: Safety profile, including incidence and severity of adverse events
timeFrame: During treatment and 28 days after last dose of rIL-21
Secondary outcomes:
measure: Objective response rate at recommended dose of rIL-21
timeFrame: Every 6 weeks during treatment and then every 3 months after last dose of rIL-21 until 3 months after median survival is reached
measure: Progression-free survival at recommended dose of rIL-21
timeFrame: Every 6 weeks during treatment and then every 3 months after last dose of rIL-21 until 3 months after median survival is reached
measure: Pharmacokinetic profiles of rIL-21 and sorafenib
timeFrame: rIL-21: During treatment and 15 days after dosing; sorafenib: During treatment and 22 days after dosing
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama
state: Alabama
city: Scottsdale
country: United States
facility: Premiere Oncology of Arizona
state: Arizona
city: Lebanon
country: United States
facility: Dartmouth-Hitchcock Medical Center
state: New Hampshire
Study officials:
affiliation: ZymoGenetics
name: Naomi Hunder, MD
role: STUDY_DIRECTOR
References:
citation: Bhatia S, Curti B, Ernstoff MS, Gordon M, Heath EI, Miller WH Jr, Puzanov I, Quinn DI, Flaig TW, VanVeldhuizen P, Byrnes-Blake K, Freeman JA, Bittner R, Hunder N, Souza S, Thompson JA. Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer. 2014 Jan 27;2:2. doi: 10.1186/2051-1426-2-2. eCollection 2014.